69
Participants
Start Date
January 31, 2009
Primary Completion Date
January 31, 2012
Study Completion Date
June 30, 2012
anakinra
The patients are instructed to administer anti-IL-1 therapy in the form of recombinant human non-glycosylated interleukin-1 receptor antagonist (IL-1Ra, anakinra, Kineret®, Amgen, CA, USA) \[13\] at a dose of 100 mg once daily by subcutaneous injection
saline
The patients are instructed to administer placebo (saline) once daily by subcutaneous injection
Steno Diabetes Center, Gentofte Municipality
Nordsjællands Hospital, Hillerød, Hillerød
Aalborg Hospital, Aalborg
Hospital Arnua de Vilanova, Lleida
Hospital Unversitario Insular de Gran Canaria, Las Palmas
Leibniz Center for Diabetes research, Heinrich-Heine University, Düsseldorf
Hospital de Cruces, Diabetes Research Group, Barakaldo
University of Frankfurt am Main, Frankfurt am Main
Institut für Diabetesforschung, Munich University of Technology, Munich
Ulm University, Dept. of Internal Medicine, Ulm
Aarhus Universitetshospital, Aarhus
Bispebjerg Universitetshospital, Copenhagen
University Campus Bio-Medico, Rome
Leiden University Medical Center, Leiden
Medical University of Bialystok, Bialystok
Hospital Santa Creu i Sant Pau, Barcelona
University Hospital Zürich, Zurich
Collaborators (1)
Juvenile Diabetes Research Foundation
OTHER
Oeresund Diabetes Academy
UNKNOWN
Steno Diabetes Center Copenhagen
OTHER